Genvoya Shortage: What Providers and Prescribers Need to Know in 2026

As of 2026, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is not on the FDA's official drug shortage list. However, prescribers managing patients on Genvoya are increasingly encountering access-related barriers — insurance delays, specialty pharmacy routing failures, and local stocking gaps — that functionally disrupt patient treatment. This guide outlines the clinical and operational landscape for prescribers.

Current Availability Status of Genvoya

Genvoya is manufactured by Gilead Sciences and has had a consistent manufacturing history since its 2015 FDA approval. It is not listed on the FDA Drug Shortage Database as of early 2026. Gilead's production infrastructure for its HIV franchise — which includes Biktarvy and Descovy — remains robust.

Despite no declared shortage, the access landscape is complex. Genvoya is a specialty-tier medication, and the distribution channels for specialty HIV medications differ significantly from conventional retail pharmacy channels. This creates structural vulnerabilities that manifest as patient-level access failures even when supply is adequate at the manufacturer level.

Root Causes of Genvoya Access Disruptions

Clinicians should be aware of the primary mechanisms driving patient-reported access failures:

Prior Authorization Lapses: The majority of commercial and Medicare Part D plans require prior authorization for Genvoya. PA renewal failures — often due to timing gaps between office workflows and insurer deadlines — are a leading cause of dispensing interruptions.

Specialty Pharmacy Network Restrictions: Most pharmacy benefit managers (PBMs) mandate that Genvoya be dispensed through a specialty pharmacy within their network. If a patient's prescription is routed incorrectly or the patient presents at a retail pharmacy, the fill will be rejected. This is system-level, not supply-level.

Formulary Step Therapy: Some payers require documentation of formulary step therapy — typically demonstrating Genvoya's clinical necessity relative to Biktarvy or other preferred agents — before authorizing coverage. This creates administrative burdens that can delay access by weeks.

Regional Stocking Gaps: Even within specialty pharmacy networks, individual locations may experience temporary stocking gaps due to wholesaler logistics, particularly in rural or underserved regions.

Clinical Risks of Genvoya Treatment Interruption

For patients on stable Genvoya therapy, treatment interruptions carry significant clinical risk:

Viral Rebound: Even brief interruptions in ART can result in HIV RNA rebound, particularly in patients with lower baseline CD4 counts or history of non-adherence.

Resistance Development: Elvitegravir has a low genetic barrier to resistance compared to dolutegravir or bictegravir. A rebound episode during an interruption could result in INSTI resistance mutations that limit future regimen options.

Hepatitis B Flare: For HBV/HIV co-infected patients, discontinuation of Genvoya (which contains emtricitabine and tenofovir alafenamide — both active against HBV) can precipitate severe hepatitis B flares. This is reflected in the drug's FDA boxed warning. Hepatic function must be monitored closely for at least several months post-discontinuation in co-infected patients.

Strategies to Prevent Patient Access Disruptions

Prescribers can take proactive steps to reduce the risk of access interruptions for patients on Genvoya:

Proactive PA Management: Implement a calendar reminder system for PA renewals at least 60 days in advance. Dedicate a staff member to tracking PA expiration dates for patients on chronic specialty medications.

Establish Specialty Pharmacy Relationships: Work with one or two specialty pharmacies that specialize in HIV medications. These pharmacies can provide proactive outreach to patients for refills and have clinical pharmacists who understand HIV regimen management.

Maintain Sample Inventory: Request Genvoya samples from Gilead's Medical Science Liaison to bridge patients in the event of short-term access gaps. Gilead's Advancing Access program can also facilitate emergency supply in documented cases.

Recommend 90-Day Supplies: Where insurance allows, prescribe 90-day supplies to reduce refill frequency and decrease the risk of administrative lapses creating access gaps.

When to Consider Switching from Genvoya

If a patient is experiencing recurrent access barriers with Genvoya, it may be appropriate to consider switching to a regimen with fewer access challenges. Key alternatives to evaluate:

Biktarvy (BIC/FTC/TAF): Currently a DHHS preferred first-line agent. Bictegravir has a higher genetic barrier to resistance than elvitegravir and does not require a pharmacokinetic booster, resulting in a simpler drug-interaction profile. Broadly available at most specialty pharmacies.

Dovato (DTG/3TC): Two-drug once-daily option with strong efficacy in virologically suppressed patients. Not appropriate for HBV co-infection, baseline HIV-1 RNA >500,000 copies/mL, or patients with NRTI resistance.

Cabenuva (CAB/RPV long-acting injectable): Eliminates daily oral pill burden entirely. Administered monthly or every 2 months by a healthcare provider. Appropriate for virologically suppressed patients without resistance to integrase inhibitors or rilpivirine.

Using medfinder to Help Locate Genvoya for Your Patients

When a patient cannot locate Genvoya at their pharmacy, medfinder for providers can help. medfinder contacts pharmacies near the patient's location to identify which ones have the medication in stock and can fill the prescription. Results are texted to the patient. This service covers all medications and is particularly useful for specialty drugs with limited local availability.

See also: How to help your patients find Genvoya in stock: A provider's guide.